Novo Nordisk's Diabetes Drug Outshines Ozempic: Buy?
A new diabetes drug from Novo Nordisk could change the GLP-1 landscape. This deep dive breaks down what investors sho...
Understanding when to shift from stocks to bonds can enhance your investment strategy. Make informed decisions to maximize returns.
22,202 articlesA new diabetes drug from Novo Nordisk could change the GLP-1 landscape. This deep dive breaks down what investors sho...
Banks are boosting checking account bonuses to attract new customers. This report breaks down how to qualify, what to...
Walmart’s stock falls after a softer-than-expected quarterly report, as U.S. store sales grow slowly and the profit o...
Cardano faces a pivotal test as founder Charles Hoskinson lays out a four-layer rescue plan blending governance refor...
Occidental Petroleum surged after announcing a $5.8 billion debt reduction tied to the OxyChem sale and an uptick in ...
Medicare's day-count cliffs push hospital costs $434 per day after day 60, rising to $868 per day after day 90. The p...
Ready to make rental properties a real pathway to retirement? This guide outlines three actionable strategies for 202...
A sudden legal issue can ripple through finances faster than an athlete can sprint. Learn how to prepare, protect, an...
As Omnicom wraps up the 2025 fiscal year, investors want clarity on growth, margins, and capital allocation. This gui...
A growing wave of Americans plans to retire at 55 to Costa Rica’s Pacific shores. The plan hinges on location-specifi...
In a landmark move, workers at the Tennessee Volkswagen plant ratified their first union contract after a two-year dr...
Choosing the right core holding matters. This guide compares SPY and QQQ, explains who each is best for, and shows ho...